整合性机器学习方法用于预测在巨症中对第一代受体配体的抗性
Wei Lin1,2, Songchang Shi3, Yuanyuan Zheng1,4
1Division of Endocrinology, Diabetes and hypertension, Brigham and Women's hospital, Harvard Medical School, Boston, MA, USA.
The Journal of clinical endocrinology and metabolism
|June 26, 2025
概括
这项研究开发了一台机器学习计算器,用于预测壮症患者的治疗反应,帮助个性化治疗. 该工具准确地识别了可能从第一代体静止素受体配体 (fgSRLs) 中受益的个体.
科学领域:
- 内分泌学 在内分泌学.
- 机器学习在医学中的应用
- 计算生物学 计算生物学
背景情况:
- 由于生长激素 (GH) 和胰岛素样生长因子-1 (IGF-1) 的过量导致的巨,通常需要第一代体静止素受体连接体 (fgSRLs) 治疗术后.
- 患者对fgSRLs治疗的反应表现出显著的变化,需要个性化治疗策略.
研究的目的:
- 创建一个基于机器学习 (ML) 的计算器,用于预测个体患者对fgSRLs治疗的反应.
- 通过预测治疗疗效,支持基于证据的壮症管理.
主要方法:
- 在2010年1月至2024年7月期间,111名在Mass General Brigham附属医院接受治疗的壮症患者的回顾性分析.
- 评估十个ML算法来预测fgSRLs电阻,选择CatBoost模型以获得最佳性能 (AUROC 0.896).
- 使用SHAP分析识别耐药性的关键预测因素,包括治疗前的GH,Knosp等级,IGF-1指数,MRI密度和并发症负担.
主要成果:
- CatBoost模型在识别fgSRLs耐药性方面实现了高预测准确度 (82.4%) 和特异性 (88.2%).
- 确定了治疗耐药性的关键预测因素,包括治疗前的GH和IGF-1水平,Knosp等级,MRI特征和整体并发症负担.
- 开发了一个基于网络的临床计算器,证明了优秀的校准和临床实用性.
结论:
- 开发的基于CatBoost的计算器在预测fgSRLs在壮症治疗反应方面表现出有效性.
- 建议在预测工具广泛临床实施之前进行进一步的前性验证.
更多相关视频
10:51Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
12.9K
08:04Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
529
相关概念视频
The Two-State Receptor Model
2.4K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
2.4K
Drug-Receptor Interactions
6.0K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
6.0K
Drug-Receptor Interaction: Agonist
2.8K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.8K
Ligand Binding Sites
13.4K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
13.4K
